Amyotrophic Lateral Sclerosis Market- Size & Forecast 2033

Request Methodology

Amyotrophic Lateral Sclerosis Market Snapshot (2023 to 2033)

The global Amyotrophic Lateral Sclerosis market is expected to garner a market value of US$ 743.90 Million in 2023 and is expected to accumulate a market value of US$ 1332.22 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The growth of the Amyotrophic Lateral Sclerosis market can be attributed to the rising geriatric population, growing awareness about ALS, and increasing incidence rate. The market for Amyotrophic Lateral Sclerosis registered a CAGR of 4% in the historical period 2017 to 2022.

Supplemental approvals for existing treatment options are likely to bolster market growth in future years. In addition to that, many renowned companies are aiming to submit their applications for approval for new drug therapies, which is another crucial factor that is estimated to aid the growth.

Report Attribute	Details
Expected Market Value (2023)	US$ 743.90 Million
Anticipated Forecast Value (2033)	US$ 1332.22 Million
Projected Growth Rate (2023 to 2033)	6% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2017 to 2022 Amyotrophic Lateral Sclerosis Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Amyotrophic Lateral Sclerosis reflected a value of 4% during the historical period, 2017 to 2022. National lockdown, government controls, and a spike in infection rates across countries all had a major financial impact on client engagement.

Amyotrophic lateral sclerosis, a progressive neurodegenerative disorder, damages nerve cells in the central nervous system responsible for controlling voluntary muscles. As per studies, around half of the people suffering from ALS may lose the ability to swallow, breathe, speak, walk, and use their hands. Thus, the market for Amyotrophic Lateral Sclerosis is expected to register a CAGR of 6% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Amyotrophic Lateral Sclerosis Market?

Increasing incidence of cancer to push the market growth

The increasing prevalence of amyotrophic lateral sclerosis disease is one of the biggest drivers of the market. According to the National Institute of Neurological Disorders and Stroke (NINDS), following gradual paralysis, patients with ALS often die from respiratory failure within 3-5 years. It also states that between the two types of ALS, the sporadic type is the most common form, accounting for 90- 95% of all cases in the USA while the familial type accounts for the rest.

In addition to this, an inclination of the population towards a stationary lifestyle and an increasing geriatric population has increased the demand for targeted and indicated treatment options, which are driving the global amyotrophic lateral sclerosis market.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Amyotrophic Lateral Sclerosis Market?

Expensive Cost of Treatment to restrict Market Growth

The expensive treatment of Amyotrophic lateral sclerosis, less awareness of amyotrophic lateral sclerosis disease, and insubstantial treatment options are hampering the market growth.

Region-Wise Insights

How is the Market for Amyotrophic Lateral Sclerosis Turning Out in the Asia Pacific Region?

Increased revenue generation propelling the growth of Amyotrophic Lateral Sclerosis in Asia Pacific

The Asia Pacific is expected to exhibit the fastest growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period.

The industry is witnessing increasing revenue generation in this region, especially in India and China. Major factors propelling the market growth in this region include growing Research and Development investment in the healthcare sector, plenty of unexplored opportunities, and promising initiatives by the manufacturers as well as the governments.

What are the Factors Boosting the Market for Amyotrophic Lateral Sclerosis in North America?

High Concentration of Key Players shaping the landscape for Amyotrophic Lateral Sclerosis in North America

North America is anticipated to acquire a market share of about 20% in the forecast period. This growth is attributable to the availability of recently developed immunosuppressants and the presence of a favorable reimbursement scenario across the USA.

It is estimated that the high healthcare expenditure along with the huge demand for ALS drugs, and established healthcare infrastructure are the factors driving the market. According to the data published in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, in 2015 around 16,583 cases of amyotrophic lateral sclerosis were identified in the USA

Besides, the presence of a large number of significant pharmaceutical companies in the USA is set to bode well for the North American market. Thus, given the aforementioned factors, the market is expected to grow significantly over the forecast period in North America.

Category-Wise Insights

Based on Treatment, Which Segment is Pushing the Market Growth?

The superior efficiency of Stem cell therapy bolsters the growth

On the basis of treatment, the segment has been divided into medications, stem cell therapies, and others. Stem cell therapy is expected to show the highest CAGR owing to the increasing demand for new approaches and advanced treatment options. In addition to this, several initiatives have been taken by the government authoritative bodies and the Collaborative ALS Drug Discovery Initiative (CADDI) to fast-track the development of novel drugs and treatments.

By Distribution Channels, Which Segment Dominates the Market?

Hospital pharmacies to drive market growth

The distribution channel segment has been divided into hospital pharmacies, retail pharmacies, and others. According to the FMI analysis, Hospital pharmacies account for the largest market share. The requirement for several hospital stays and visits during ALS treatment facilitates the growth of this segment.

Start-up in the Amyotrophic Lateral Sclerosis Market

Key start-up players in the Amyotrophic Lateral Sclerosis market are-

Since its founding in Tel Aviv in 2017, neurodegenerative disease start-up NeuroSense Therapeutics has been eyeing the USA market. Now, the company (Nasdaq: NRSN) is using its local headquarters in Cambridge to anchor its efforts to advance a drug that aims to treat amyotrophic lateral sclerosis (ALS).
QurAlis has raised seed funding from a syndicate featuring Amgen Ventures. The start-up will use the cash to advance treatments for three subtypes of amyotrophic lateral sclerosis (ALS). Amgen joined with MP Healthcare Venture Management and Alexandria Venture Investments to put the latest tranche of funding into QurAlis, which bankrolled its early days using money from friends and family investors. Bringing the new investors on board equips QurAlis to advance programs based on an understanding of the genetics and biomarkers associated with different types of ALS.

Market Competition

Key players in the Amyotrophic Lateral Sclerosis market are Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co., Ltd.; BrainStorm Therapeutics; Biogen Inc.; Corestem; AB Science; F.Hoffmann-La Roche AG; Biohaven Pharmaceutical; Sun Pharmaceutical; and Ionis Pharmaceuticals, Inc.

In June 2021, CRISPR Therapeutics and Capsida Biotherapeutics Inc. entered into a strategic partnership to research, develop, manufacture, and commercialize in vivo gene editing therapies using CRISPR technology delivered with engineered AAV vectors for the treatment of familial amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia. Such partnerships are likely to bolster market growth.
In June 2022, Canada approved Amylyx Pharmaceuticals Inc’s new drug ALBRIOZA (also known as AMX0035) for amyotrophic lateral sclerosis.

Report Scope

Report Attribute	Details
Market Value in 2023	US$ 743.90 Million
Market Value in 2033	US$ 1332.22 Million
Growth Rate	CAGR of 6% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2017 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Treatment Distribution Channel Region
Regions Covered	North America Latin America Europe Asia Pacific Middle East and Africa (MEA)
Key Countries Profiled	USA Canada Brazil Argentina Germany UK France Spain Italy Nordics BENELUX Australia & New Zealand China India ASIAN GCC Countries South Africa
Key Companies Profiled	Mitsubishi Tanabe Pharma Corporation Otsuka Pharmaceutical Co., Ltd. BrainStorm Therapeutics Biogen Inc. Corestem AB Science F.Hoffmann-La Roche AG Biohaven Pharmaceutical Sun Pharmaceutical Ionis Pharmaceuticals, Inc.
Customization	Available Upon Request

Key Segments Profiled in the Amyotrophic Lateral Sclerosis Industry Survey

Treatment:

Medication
Stem Cell Therapy
Others

Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Others

Region:

North America
Latin America
Europe
Asia Pacific
Middle East and Africa (MEA)

Frequently Asked Questions

At what rate did the Amyotrophic Lateral Sclerosis market flourish from 2017 to 2022?

From 2017 to 2022, the Amyotrophic Lateral Sclerosis market grew at a CAGR of 4%.

What will be the growth rate of the global Amyotrophic Lateral Sclerosis market during the forecast period?

The global Amyotrophic Lateral Sclerosis market is expected to grow with a 6% CAGR from 2023 to 2033.

What will be the projected market size of the Amyotrophic Lateral Sclerosis market by 2033?

As of 2033, the Amyotrophic Lateral Sclerosis market is expected to reach US$ 1332.22 Million

Which distribution segment is expected to dominate the global Amyotrophic Lateral Sclerosis market during 2033?

According to the FMI analysis, Hospital pharmacies account for the largest market share.

Which type of treatment is expected to dominate the global Amyotrophic Lateral Sclerosis market during 2033?

Stem cell therapy is expected to show the highest CAGR owing to the increasing demand for new approaches.

How is the North America Amyotrophic Lateral Sclerosis market projected to grow in 2033?

North America is expected to possess 20% market share for Amyotrophic Lateral Sclerosis market.

How is the Asia Pacific Amyotrophic Lateral Sclerosis market projected to grow in 2033?

The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.

Table of Content

1. Executive Summary | Amyotrophic Lateral Sclerosis Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

5.3.1. Medication

5.3.2. Stem Cell Therapy

5.3.3. Others

5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

6.3.1. Hospital Pharmacies

6.3.2. Retail Pharmacies

6.3.3. Others

6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

7.1. Introduction

7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

7.3.1. North America

7.3.2. Latin America

7.3.3. Europe

7.3.4. Asia Pacific

7.3.5. Middle East and Africa (MEA)

7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

8.2.1. By Country

8.2.1.1. United States of America

8.2.1.2. Canada

8.2.2. By Treatment

8.2.3. By Distribution Channel

8.3. Market Attractiveness Analysis

8.3.1. By Country

8.3.2. By Treatment

8.3.3. By Distribution Channel

8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

9.2.1. By Country

9.2.1.1. Brazil

9.2.1.2. Mexico

9.2.1.3. Rest of Latin America

9.2.2. By Treatment

9.2.3. By Distribution Channel

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Treatment

9.3.3. By Distribution Channel

9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

10.2.1. By Country

10.2.1.1. Germany

10.2.1.2. United Kingdom

10.2.1.3. France

10.2.1.4. Spain

10.2.1.5. Italy

10.2.1.6. Rest of Europe

10.2.2. By Treatment

10.2.3. By Distribution Channel

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Treatment

10.3.3. By Distribution Channel

10.4. Key Takeaways

11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

11.2.1. By Country

11.2.1.1. China

11.2.1.2. Japan

11.2.1.3. South Korea

11.2.1.4. Singapore

11.2.1.5. Thailand

11.2.1.6. Indonesia

11.2.1.7. Australia

11.2.1.8. New Zealand

11.2.1.9. Rest of Asia Pacific

11.2.2. By Treatment

11.2.3. By Distribution Channel

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Treatment

11.3.3. By Distribution Channel

11.4. Key Takeaways

12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

12.2.1. By Country

12.2.1.1. GCC Countries

12.2.1.2. South Africa

12.2.1.3. Israel

12.2.1.4. Rest of MEA

12.2.2. By Treatment

12.2.3. By Distribution Channel

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Treatment

12.3.3. By Distribution Channel

12.4. Key Takeaways

13. Key Countries Market Analysis

13.1. United States of America

13.1.1. Pricing Analysis

13.1.2. Market Share Analysis, 2022

13.1.2.1. By Treatment

13.1.2.2. By Distribution Channel

13.2. Canada

13.2.1. Pricing Analysis

13.2.2. Market Share Analysis, 2022

13.2.2.1. By Treatment

13.2.2.2. By Distribution Channel

13.3. Brazil

13.3.1. Pricing Analysis

13.3.2. Market Share Analysis, 2022

13.3.2.1. By Treatment

13.3.2.2. By Distribution Channel

13.4. Mexico

13.4.1. Pricing Analysis

13.4.2. Market Share Analysis, 2022

13.4.2.1. By Treatment

13.4.2.2. By Distribution Channel

13.5. Germany

13.5.1. Pricing Analysis

13.5.2. Market Share Analysis, 2022

13.5.2.1. By Treatment

13.5.2.2. By Distribution Channel

13.6. United Kingdom

13.6.1. Pricing Analysis

13.6.2. Market Share Analysis, 2022

13.6.2.1. By Treatment

13.6.2.2. By Distribution Channel

13.7. France

13.7.1. Pricing Analysis

13.7.2. Market Share Analysis, 2022

13.7.2.1. By Treatment

13.7.2.2. By Distribution Channel

13.8. Spain

13.8.1. Pricing Analysis

13.8.2. Market Share Analysis, 2022

13.8.2.1. By Treatment

13.8.2.2. By Distribution Channel

13.9. Italy

13.9.1. Pricing Analysis

13.9.2. Market Share Analysis, 2022

13.9.2.1. By Treatment

13.9.2.2. By Distribution Channel

13.10. China

13.10.1. Pricing Analysis

13.10.2. Market Share Analysis, 2022

13.10.2.1. By Treatment

13.10.2.2. By Distribution Channel

13.11. Japan

13.11.1. Pricing Analysis

13.11.2. Market Share Analysis, 2022

13.11.2.1. By Treatment

13.11.2.2. By Distribution Channel

13.12. South Korea

13.12.1. Pricing Analysis

13.12.2. Market Share Analysis, 2022

13.12.2.1. By Treatment

13.12.2.2. By Distribution Channel

13.13. Singapore

13.13.1. Pricing Analysis

13.13.2. Market Share Analysis, 2022

13.13.2.1. By Treatment

13.13.2.2. By Distribution Channel

13.14. Thailand

13.14.1. Pricing Analysis

13.14.2. Market Share Analysis, 2022

13.14.2.1. By Treatment

13.14.2.2. By Distribution Channel

13.15. Indonesia

13.15.1. Pricing Analysis

13.15.2. Market Share Analysis, 2022

13.15.2.1. By Treatment

13.15.2.2. By Distribution Channel

13.16. Australia

13.16.1. Pricing Analysis

13.16.2. Market Share Analysis, 2022

13.16.2.1. By Treatment

13.16.2.2. By Distribution Channel

13.17. New Zealand

13.17.1. Pricing Analysis

13.17.2. Market Share Analysis, 2022

13.17.2.1. By Treatment

13.17.2.2. By Distribution Channel

13.18. GCC Countries

13.18.1. Pricing Analysis

13.18.2. Market Share Analysis, 2022

13.18.2.1. By Treatment

13.18.2.2. By Distribution Channel

13.19. South Africa

13.19.1. Pricing Analysis

13.19.2. Market Share Analysis, 2022

13.19.2.1. By Treatment

13.19.2.2. By Distribution Channel

13.20. Israel

13.20.1. Pricing Analysis

13.20.2. Market Share Analysis, 2022

13.20.2.1. By Treatment

13.20.2.2. By Distribution Channel

14. Market Structure Analysis

14.1. Competition Dashboard

14.2. Competition Benchmarking

14.3. Market Share Analysis of Top Players

14.3.1. By Regional

14.3.2. By Treatment

14.3.3. By Distribution Channel

15. Competition Analysis

15.1. Competition Deep Dive

15.1.1. Mitsubishi Tanabe Pharma Corporation

15.1.1.1. Overview

15.1.1.2. Product Portfolio

15.1.1.3. Profitability by Market Segments

15.1.1.4. Sales Footprint

15.1.1.5. Strategy Overview

15.1.1.5.1. Marketing Strategy

15.1.2. Otsuka Pharmaceutical Co., Ltd.

15.1.2.1. Overview

15.1.2.2. Product Portfolio

15.1.2.3. Profitability by Market Segments

15.1.2.4. Sales Footprint

15.1.2.5. Strategy Overview

15.1.2.5.1. Marketing Strategy

15.1.3. BrainStorm Therapeutics

15.1.3.1. Overview

15.1.3.2. Product Portfolio

15.1.3.3. Profitability by Market Segments

15.1.3.4. Sales Footprint

15.1.3.5. Strategy Overview

15.1.3.5.1. Marketing Strategy

15.1.4. Biogen Inc.

15.1.4.1. Overview

15.1.4.2. Product Portfolio

15.1.4.3. Profitability by Market Segments

15.1.4.4. Sales Footprint

15.1.4.5. Strategy Overview

15.1.4.5.1. Marketing Strategy

15.1.5. Corestem

15.1.5.1. Overview

15.1.5.2. Product Portfolio

15.1.5.3. Profitability by Market Segments

15.1.5.4. Sales Footprint

15.1.5.5. Strategy Overview

15.1.5.5.1. Marketing Strategy

15.1.6. AB Science

15.1.6.1. Overview

15.1.6.2. Product Portfolio

15.1.6.3. Profitability by Market Segments

15.1.6.4. Sales Footprint

15.1.6.5. Strategy Overview

15.1.6.5.1. Marketing Strategy

15.1.7. F.Hoffmann-La Roche AG

15.1.7.1. Overview

15.1.7.2. Product Portfolio

15.1.7.3. Profitability by Market Segments

15.1.7.4. Sales Footprint

15.1.7.5. Strategy Overview

15.1.7.5.1. Marketing Strategy

15.1.8. Biohaven Pharmaceutical

15.1.8.1. Overview

15.1.8.2. Product Portfolio

15.1.8.3. Profitability by Market Segments

15.1.8.4. Sales Footprint

15.1.8.5. Strategy Overview

15.1.8.5.1. Marketing Strategy

15.1.9. Sun Pharmaceutical

15.1.9.1. Overview

15.1.9.2. Product Portfolio

15.1.9.3. Profitability by Market Segments

15.1.9.4. Sales Footprint

15.1.9.5. Strategy Overview

15.1.9.5.1. Marketing Strategy

15.1.10. Ionis Pharmaceuticals, Inc.

15.1.10.1. Overview

15.1.10.2. Product Portfolio

15.1.10.3. Profitability by Market Segments

15.1.10.4. Sales Footprint

15.1.10.5. Strategy Overview

15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 15: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 18: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 62: Asia Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 70: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 73: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033

Figure 74: Asia Pacific Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 76: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 77: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 85: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 86: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 87: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 88: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 89: MEA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 90: MEA Market Attractiveness by Country, 2023 to 2033

December 2022

REP-GB-16174

300 pages

Healthcare

Sabyasachi Ghosh

Book Now

Clients

Customize This Research

Quick Contact

Chat on Whatsapp + 44 (0) 20 3287 4268 + 44 (0) 20 8123 9659 + 1 347 918 3531 Contact By Email

- Trust FMI -

- Member of -

Greater New York Chamber of Commerce

- Awarded by -

BRONZE STEVIE® Award

20th annual IBAs

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

- Recognized by -

Amyotrophic Lateral Sclerosis Market

Market Survey on Amyotrophic Lateral Sclerosis Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment